甘氨胆酸
甘氨胆酸 性质
| 熔点 | 128°C |
|---|---|
| 沸点 | 568.76°C (rough estimate) |
| 密度 | 1.1336 (rough estimate) |
| 折射率 | 1.6000 (estimate) |
| 储存条件 | Refrigerator |
| 溶解度 | 甲醇：0.1 g/mL，澄清，无色 |
| 形态 | 固体 |
| 酸度系数(pKa) | 4.4(at 25℃) |
| 颜色 | 白色至类白色 |
| 水溶解性 | 329.9mg/L(20 ºC) |
| Merck | 13,4507 |
| 稳定性 | 吸湿性 |
| InChIKey | RFDAIACWWDREDC-NSPZZGDONA-N |
| LogP | 1.650 |
| CAS 数据库 | 475-31-0(CAS DataBase Reference) |
| NIST化学物质信息 | Glycocholic acid(475-31-0) |
甘氨胆酸 用途与合成方法
|
Human Endogenous Metabolite
|
Glycocholic acid (GC) increases the cytotoxicity of epirubicin, significantly increases the intracellular accumulation of epirubicin in Caco-2 cells and the absorption of epirubicin in rat small intestine, and intensified epirubicin-induced apoptosis. Glycocholic acid and epirubicin significantly reduce mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulate the MDR1 promoter region; suppress the mRNA expression of Bcl-2; induce the mRNA expression of Bax; and significantly increase the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3. A combination of anticancer drugs with Glycocholic acid can control MDR via a mechanism that involves modulating P-gp and MRPs as well as regulating apoptosis-related pathways.
甘氨胆酸 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-11 | XW04753102 | 甘氨胆酸 | 475-31-0 | 1G | 75 |
| 2024-11-11 | XW04753101 | 甘氨胆酸 | 475-31-0 | 250MG | 36 |
